MEDPLUS: Revenue rose 21.3% YoY as Q2 reported Operating EBITDA reached ₹981m

What happened

MedPlus reported Q2 revenue grew 21.3% year over year to ₹20,371m, while reported Operating EBITDA rose 10.7% to ₹981m. Store expansion and mature-store growth supported the quarter, but H1 PAT declined 8.8% year over year.

Confirmed

Global impact / market context

Revenue growth of 21.3% is much faster than Operating EBITDA growth of 10.7%, which means profit per sale narrowed as sales expanded. H1 PAT falling 8.8% shows higher sales did not carry through to bottom-line profit, a gap investors will weigh.

Analyst inference

The results point to a pharmacy retailer adding stores and growing existing outlets while profit per sale came under pressure. Store expansion typically adds rent, staff and other operating costs before new outlets mature, which can weigh on profit even as revenue rises.

Analyst inference

What to watch

1. H1 PAT declined 8.8% year over year, so watch whether the profit gap persists in later periods even as revenue grows. Confirmed
2. Watch whether MedPlus discloses the split between new-store and mature-store growth, since new stores often carry costs before they become profitable. Proposed
3. Track whether Operating EBITDA growth closes the gap with revenue growth, which would signal profit per sale stabilizing as expansion costs ease. Analyst inference

Evidence

• Original source link unavailable